User:Mr. Ibrahem/Axitinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Axitinib
Clinical data
Trade namesInlyta, Axinix
Other namesAG013736
AHFS/Drugs.comMonograph
MedlinePlusa612017
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classTyrosine kinase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability58%[3]
Protein binding>99%[3]
MetabolismLiver (mostly CYP3A4/CYP3A5-mediated but with some contributions from CYP1A2, CYP2C19, UGT1A1)[3]
Elimination half-life2.5-6.1 hours[3]
ExcretionFeces (41%; 12% as unchanged drug), urine (23%)[3]
Identifiers
  • N-Methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
Chemical and physical data
FormulaC22H18N4OS
Molar mass386.47 g·mol−1
3D model (JSmol)
  • CNC(=O)c1ccccc1Sc4ccc3c(C=Cc2ccccn2)n[nH]c3c4
  • InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ checkY
  • Key:RITAVMQDGBJQJZ-FMIVXFBMSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Axitinib, sold under the brand name Inlyta, is a medication used to treat renal cell cancer (RCC).[4] It is used in advanced disease, either alone or with avelumab or pembrolizumab.[4] It increased time to getting worse to 6.7 months from 4.7 months in those taking sorafenib.[5] It is taken by mouth.[4]

Common side effects include diarrhea, high blood pressure, tiredness, nausea, weight loss, weakness, and constipation.[4] Other side effects may include blood clots, bleeding, heart failure, gastrointestinal perforation, low thyroid, poor wound healing, liver problems, and reversible posterior leukoencephalopathy syndrome (RPLS).[4] Use in pregnancy may harm the baby.[4] It is a tyrosine kinase inhibitor that blocks vascular endothelial growth factor (VEGF).[1]

Axitinib was approved for medical use in the United States and Europe in 2012.[5][4] In the United Kingdom 4 weeks of treatments costs the NHS about £3,500 as of 2021.[6] In the United States this amount costs about 17,300 USD.[7]

References[edit]

  1. ^ a b "Axitinib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 17 January 2022.
  2. ^ "Inlyta- axitinib tablet, film coated". DailyMed. Pfizer Inc. Archived from the original on 27 November 2019. Retrieved 25 January 2014.
  3. ^ a b c d e "Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 5 July 2018. Retrieved 25 January 2014.
  4. ^ a b c d e f g h i j "DailyMed - INLYTA- axitinib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 27 June 2021. Retrieved 17 January 2022.
  5. ^ a b "Inlyta". Archived from the original on 8 October 2021. Retrieved 17 January 2022.
  6. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1013. ISBN 978-0857114105.
  7. ^ "Inlyta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 17 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Axitinib&oldid=1099505492"